Table 2.
Therapy history for each morphologic group by tumor site – primary/metastatic disease
| Cancer Location | Number of Cases (N=) | Therapy | ||||
|---|---|---|---|---|---|---|
| RT | ADT | RT+ADT | NONE | |||
| Small cell carcinoma / HGNEC | Total | 23 | 3 | 5 | 12 | 3 |
| Primary | 3 | 1 | 0 | 0 | 2 | |
| Metastatic | 20 | 2 | 5 | 12 | 1 | |
| Combined adenocarcinoma + small cell carcinoma / HGNEC | Total | 10 | 0 | 6 | 3 | 1 |
| Primary | 9 | 0 | 6 | 2 | 1 | |
| Metastatic | 1 | 0 | 0 | 1 | 0 | |
| PCa with diffuse NE marker positivity / differentiation | Total | 15 | 1 | 3 | 8 | 3 |
| Primary | 0 | 0 | 0 | 0 | 0 | |
| Metastatic | 15 | 1 | 3 | 8 | 3 | |
| PCa with patchy NE differentiation | Total | 11* | 0 | 3 | 5 | 2 |
| Primary | 5 | 0 | 2 | 1 | 2 | |
| Metastatic | 6 | 0 | 1 | 4 | 0 | |
| PCa with isolated NE marker positive cells | Total | 9* | 0 | 4 | 2 | 1 |
| Primary | 4 | 0 | 2 | 1 | 1 | |
| Metastatic | 5 | 0 | 2 | 1 | 0 | |
| PCa with prominent NE granules (‘Paneth cell-like’) | Total | 11 | 2 | 3 | 3 | 3 |
| Primary | 11 | 2 | 3 | 3 | 3 | |
| Metastatic | 0 | 0 | 0 | 0 | 0 | |
*
One case of PCa with patchy NE differentiation and 2 cases of PCa with isolated NE marker positive cells had no therapy history available
HGNEC: high-grade neuroendocrine carcinoma; PCa: prostate cancer; NE: neuroendocrine; RT: radiation therapy; ADT: androgen deprivation therapy